Thoracic Oncology
TheraOp gGmbH is engaged in clinical research for locally advanced non-small-cell lung cancer, with a focus on unresectable stage III disease and tumors showing PD-L1 expression.
- Non-small-cell lung cancer
- Locally advanced unresectable disease
- Stage III lung cancer
- PD-L1-positive tumors
The sponsor’s research activity centers on treatment strategies for advanced lung malignancy in a setting where local control and systemic disease management are both clinically relevant.
Radiation Oncology
The funded trial addresses chemoradiotherapy in lung cancer, with interest in FDG-PET-based treatment planning and accelerated radiotherapy approaches.
- Chemoradiotherapy
- FDG-PET imaging
- Accelerated radiotherapy
- Small-volume treatment concepts
These areas reflect attention to precision-guided local treatment in thoracic cancer care.
Immuno-Oncology
TheraOp gGmbH is involved in research combining immunotherapy with lung cancer treatment, specifically using durvalumab after chemoradiation.
- Immunotherapy
- Durvalumab
- Post-chemoradiation treatment
- Checkpoint inhibitor-based care
The therapeutic interest lies in integrating immune-based treatment into the management of advanced thoracic malignancy.
Functional Imaging
The sponsor’s research includes FDG-PET as a core imaging tool for defining treatment volumes and supporting individualized care in lung cancer.
- FDG-PET
- Imaging-guided treatment selection
- Target volume assessment
- Metabolic imaging
Interest in functional imaging highlights the role of metabolic information in shaping thoracic oncology treatment strategies.
